Profund Advisors LLC grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 68.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,194 shares of the specialty pharmaceutical company’s stock after buying an additional 4,543 shares during the quarter. Profund Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $299,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Sei Investments Co. boosted its stake in Supernus Pharmaceuticals by 2.1% during the 2nd quarter. Sei Investments Co. now owns 337,658 shares of the specialty pharmaceutical company’s stock valued at $9,032,000 after purchasing an additional 7,078 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Supernus Pharmaceuticals by 100,186.3% during the second quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after buying an additional 1,348,508 shares during the last quarter. Intech Investment Management LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth $303,000. XTX Topco Ltd purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $419,000. Finally, Edgestream Partners L.P. bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $2,029,000.
Supernus Pharmaceuticals Price Performance
Shares of NASDAQ:SUPN opened at $30.75 on Friday. The company has a market capitalization of $1.69 billion, a PE ratio of -106.03 and a beta of 0.88. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $35.44. The business has a fifty day moving average price of $32.27 and a two-hundred day moving average price of $30.43.
Analysts Set New Price Targets
SUPN has been the subject of several analyst reports. Piper Sandler downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $41.00 to $36.00 in a report on Wednesday, September 11th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.
Get Our Latest Stock Report on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Read More
- Five stocks we like better than Supernus Pharmaceuticals
- 10 Best Airline Stocks to Buy
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Upcoming IPO Stock Lockup Period, Explained
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.